Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Colorectal carcinoma (CRC) constitutes a common malignancy with limited therapeutic options in metastasized stages. Mesenchymal stem cells (MSC) home to tumours and may therefore serve as a novel therapeutic tool for intratumoral delivery of antineoplastic factors. Tumour necrosis factor (TNF)‐related apoptosis inducing ligand (TRAIL) which promises apoptosis induction preferentially in tumour cells represents such a factor. We generated TRAIL‐MSC by transduction of human MSC with a third generation lentiviral vector system and analysed their characteristics and capacity to inhibit CRC growth. (1) TRAIL‐MSC showed stable transgene expression with neither changes in the defining MSC characteristics nor signs of malignant transformation. (2) Upon direct in vitro coculture TR AIL‐MSC induced apoptosis in TRAIL‐sensitive CRC‐cell lines (DLD‐1 and HCT‐15) but also in CRC‐cell lines resistant to soluble TRAIL (HCT‐8 and SW480). (3) In mixed subcutaneous (s.c.) xenografts TRAIL‐MSC inhibited CRC‐tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL‐MSC within the total tumour cell number was needed to yield such anti‐tumour effect. (4) Systemic application of TRAIL‐MSC had no effect on the growth of s.c. DLD‐1 xenografts which appeared to be due to a pulmonary entrapment and low rate of tumour integration of TRAIL‐MSC. Systemic TRAIL‐MSC caused no toxicity in this model. (5) Wild‐type MSC seemed to exert a tumour growth‐supporting effect in mixed s.c. DLD‐1 xenografts. These novel results support the idea that lentiviral TRAIL‐transgenic human MSC may serve as vehicles for clinical tumour therapy but also highlight the need for further investigations to improve tumour integration of transgenic MSC and to clarify a potential tumour‐supporting effect by MSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 2×
“As in vitro cultured MSC populations may contain a considerable amount of quiescent cells [20], the use of lentiviral systems which allow an efficient genomic transgene integration even in quiescent cells seems favourable [21, 22].”
BackgroundMethodMesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“However, tumour integration [7, 38, 39] and even proliferation [8] of systemically applied MSC was seen in s.”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 4×
“MSC with transgenic expression of anti-tumour genes have the potential to exert a strong inhibitory effect on tumour growth (reviewed in [2–4]) in models of systemic application [7, 30], in mixed s.”
BackgroundInfluentialRamasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386
Hung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0876 · Cited by 268 · cited 2×
“However, tumour integration [7, 38, 39] and even proliferation [8] of systemically applied MSC was seen in s.”
BackgroundEarlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells
Djouad, F., Bony, C., Apparailly, F., Louis-Plence, P., Jorgensen, C., & Noël, D. (2006) · Transplantation · doi:10.1097/01.tp.0000236098.13804.0b · Cited by 134
Cited by
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Kuhn, N. Z., & Tuan, R. S. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21940 · Cited by 270
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
“[60].”
Metadata
- Authors
- Luetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., & Schmoll, H.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2009-06-05
- Volume
- 14
- Issue
- 9
- Pages
- 2292-2304
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2043785981
- Cited by
- 72
- References
- 10
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence. https://app.cochat.ai/papers/10.1111/j.1582-4934.2009.00794.x
- The paper
- Luetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., & Schmoll, H. (2010). Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2009.00794.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.